BioVie Completes Enrollment Of 60 Patients In Phase 2 SUNRISE-PD Clinical Trial Evaluating Bezisterim On Motor And Non-Motor Symptoms In Individuals With Early-Stage PD

- Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone -

- Topline Results from the SUNRISE-PD Trial Expected in 1H 2026 -

CARSON CITY, Nev., Jan. 08, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it has completed enrollment of 60 patients in its Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of bezisterim (NE3107) on motor and non-motor symptoms in individuals with early-stage Parkinson's disease (PD) who have not been treated with carbidopa/levodopa.

SUNRISE-PD explores whether bezisterim can affect the progression of Parkinson's symptoms in patients diagnosed with PD within the past four years who need treatment for their symptoms. The trial uses a hybrid, decentralized Phase 2 trial designed to reduce common barriers to participation in PD research, including delayed diagnosis, limited mobility, geographic constraints, and access to specialized care. The study's flexible design allows participants to complete their study visits either at home or in a clinic, improving access and flexibility while maintaining rigorous data quality and centralized oversight. Completion of enrollment for SUNRISE-PD reflects strong engagement from the PD community and highlights the feasibility of patient-centric trial designs in PD research.